Monoclonal Antibodies and Cancer
A monoclonal antibody (MAb) is an antibody made from a single clone (hybridoma) of white blood cells. MAbs are used to block key receptors on tumor cell surfaces, compromising their function. MAbs may also be used to recruit the cellular arm of the immune system, planting a homing beacon on the transformed cell. MAbs, although produced in the laboratory, mimic the antibodies naturally produced by the body as part of immune system’s response to disease. The remarkable specificity of MAbs is also being harnessed in other ways, e.g., they are being paired with powerful toxins to create specific agents that seek out cancer cells and kill them. MAbs are also being employed for diagnosis, helping to identify the source of a tumor and provide a possibility for the treatment. MAbs enable the combination of diagnostics with therapeutics.
KeywordsEpidermal Growth Factor Receptor Gemtuzumab Ozogamicin Bispecific Antibody Brentuximab Vedotin Tumor Cell Surface
- Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087-98.Google Scholar
- Judy BF, Aliperti LA, Predina JD, et al. Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia 2012;14:352-9.Google Scholar
- Scott AM, Gill SS, Lee F, et al. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 2006;Vol 24 Part I (Supplement 18S): Abstract No.13028.Google Scholar
- Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012;12:14.Google Scholar